Tata Elxsi: standalone PAT +10% YoY to ₹170 Cr as EBITDA margin recovers a quarter early
PAT +10% YoY · revenue +14.98% · margins flat · beat vs street
₹1,055.66 Cr
+14.98% YoY
₹170.3 Cr
+10% YoY
15.62%
-0.4pp YoY
₹27.34
Tata Elxsi's standalone Q2 FY27 (quarter ended September 30, 2026) results — audited, not a limited review — show revenue from operations of ₹1,055.66 Cr, up 14.98% YoY (₹918.10 Cr) and 3.38% QoQ (₹1,021.11 Cr). Net profit rose 10.0% YoY to ₹170.30 Cr (₹154.82 Cr a year ago) but was essentially flat QoQ, down 0.18% from ₹170.60 Cr in Q1 FY27. Basic EPS was ₹27.34 against ₹27.38 in Q1 and ₹24.85 a year ago. The company has no subsidiary, associate or joint venture as of September 30, 2026, so this standalone statement is the complete, primary picture — there is no separate consolidated filing to reconcile against.
Q2 FY-2027 vs prior quarters
The margin picture is split. Core operating margin (EBITDA on revenue — revenue less materials, employee cost and other expenses) expanded to 21.93% from 21.15% in Q1 FY27 and 21.06% a year ago, even as employee benefits expense rose 5.4% QoQ on wage hikes. That is notable against management's own Q1-call guidance, which flagged margin pressure in Q2 from wage hikes with only a "sequential margin ramp-up from Q3 onwards" — the ramp arrived a quarter early. Operating profit (revenue less total expenses) climbed 23.1% YoY to ₹204.19 Cr, outgrowing both revenue and PAT. But net margin (PAT on total income) actually slipped to 15.62% from 16.06% in Q1 and 16.01% a year ago, because other income fell 28.6% YoY and 15.8% QoQ to ₹34.91 Cr, and the effective tax rate rose to 28.77% from 26.61% in Q1 and 27.90% a year ago. In short: the core business margin genuinely recovered ahead of schedule; the bottom-line ratio compression sits on lower non-operating income and a higher tax charge, not on operating execution.
The stock went into the print at ₹3,426.7, up 0.5% over the past month of trading.
Management is confident in continuing the growth momentum in the media and communication and transportation verticals for the next two to three quarters, aspiring for high-single-digit growth for FY27, contingent on healthcare segment performance. While Q1 saw investments in specialized talent, AI infrastructure, and p
— This quarter: beat
Our pre-result preview flagged this quarter as a "margin recovery credibility test," with Street split between Sell-leaning brokerages (ICICI Securities, Motilal Oswal) and a minority of bulls (HDFC Securities, Prabhudas Lilladher); its on-plan estimates were revenue of ~₹1,025 Cr and PAT of ₹80-100 Cr. Actual revenue of ₹1,055.66 Cr and PAT of ₹170.30 Cr both came in well above those markers — a clear beat — though the PAT estimate range looks stale against trailing actuals (Q1 FY27 PAT alone was already ₹170.60 Cr) and should be read with that caveat. H1 FY27 revenue of ₹2,076.76 Cr is up 14.72% YoY, already running ahead of management's stated "high-single-digit" FY27 growth aspiration from the Q1 call, though that aspiration was made contingent on the healthcare segment, which this filing's two-way segment split (software development & services; system integration & support services) does not break out. Segment-wise, software development & services — 98% of revenue — grew 15.0% YoY to ₹1,027.87 Cr at a 30.5% segment margin; system integration & support was flat at ₹27.79 Cr. No management press release was available in our records to cross-check against the numbers. The quarter also saw a strategic AI investment in KAVIA AI (Sep 10), an eVTOL partnership with Sarla Aviation (Sep 1) and a healthcare-tech tie-up with SCTIMST (Jul 27) — none yet revenue-bearing — and a ₹67.3 lakh income-tax penalty order (Jul 20) that is immaterial to the P&L.
W1
Whether the 21.93% OPM holds or extends further in Q3-Q4 FY27 against management's guided 'sequential margin ramp-up from Q3 onwards'
W2
Whether revenue growth (H1 FY27 +14.72% YoY) sustains its mid-teens pace or decelerates toward management's lower 'high-single-digit' FY27 aspiration, which it flagged as contingent on the healthcare segment
W3
Whether other income (down 28.6% YoY to ₹34.91 Cr) and the effective tax rate (28.77%, up from 27.90% YoY) normalize, since both are currently the main drag on net margin despite operating-line improvement
Standalone only — company confirms (note 5) no subsidiary/associate/JV as of Sep 30, 2026, so no consolidated statement exists; figures are from a full audit (unmodified opinion), not a limited review; no exceptional item this quarter (FY26's ₹95.69 Cr New Labour Codes one-off sat in a different period and doesn't affect this YoY comparison); arithmetic ties out exactly to the lakh.
Informational and educational content only. Not investment advice.